Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Hisoar Pharma Invests RMB 150 Million in Wanbangde’s WP205 for ALS, Securing 15 % Global Revenue Share

Fineline Cube Jan 13, 2026
Company Deals

Bayer AG Acquires Cardiac Amyloidosis Imaging Tracers from Attralus, Including Phase III AT‑01 with FDA Breakthrough Designation

Fineline Cube Jan 13, 2026
Company Deals

RemeGen Licenses RC148 Bispecific to AbbVie for Up to $5.6 Billion in Milestones

Fineline Cube Jan 13, 2026
Company Deals

Boehringer Ingelheim & Jazz Launch Phase I HER2 Breast Cancer Combo with Zongertinib & Zanidatamab

Fineline Cube Jan 13, 2026
Company Deals Digital

Thermo Fisher Scientific Partners with NVIDIA in $280 Million AI Deal to Automate Laboratory Operations

Fineline Cube Jan 13, 2026
Policy / Regulatory

NHSA Launches 6th VBP Tender for Medical Consumables in China, Targeting Drug-Coated Balloons

Fineline Cube Jan 13, 2026
Company Drug

Hengrui’s HRS-7535 GLP-1R Agonist Cleared for Hypertension with Obesity Study in China

Fineline Cube Jan 13, 2026
Company Drug

Merck and Abbisko’s Pimicotinib NDA Accepted by FDA for TGCT, Building on China Approval

Fineline Cube Jan 13, 2026
Policy / Regulatory

National Reimbursement Drug List (NRDL) Negotiations Conclude with Lower Generic Drug Approval Rate

Fineline Cube Nov 1, 2024

The National Reimbursement Drug List (NRDL) negotiations for the year have concluded, with less than...

Company

MSD Reports 4% YOY Revenue Increase in Q3 2024, Led by Pharmaceutical Sector

Fineline Cube Nov 1, 2024

US pharmaceutical giant Merck, Sharp & Dohme Inc., (MSD; NYSE: MRK) has released its financial...

Company

Regeneron Pharmaceuticals Reports 11% YOY Revenue Growth in Q3 2024

Fineline Cube Nov 1, 2024

US-based Regeneron Pharmaceuticals (NASDAQ: REGN) has reported its financial details for the third quarter of...

Company Deals

AbbVie Partners with EvolveImmune to Develop Immunotherapies for Cancer

Fineline Cube Nov 1, 2024

US pharmaceutical company AbbVie (NYSE: ABBV) has entered into a collaboration and option-to-license agreement with...

Company Drug

CARsgen Therapeutics’ Suspended CAR-T Therapies Get FDA Green Light to Resume

Fineline Cube Nov 1, 2024

The US Food and Drug Administration (FDA) has removed the suspension on clinical studies for...

Company Drug

AIM Vaccine Submits Market Filing for 13-Valent Pneumococcal Conjugate Vaccine in China

Fineline Cube Nov 1, 2024

China-based AIM Vaccine Co., Ltd (HKG: 6660) has announced the submission of a market filing...

Company Drug

Eisai and Biogen Complete BLA Submission for Alzheimer’s Drug Leqembi to FDA

Fineline Cube Nov 1, 2024

Eisai Co., Ltd (TYO: 4523) and Biogen Inc. (NASDAQ: BIIB) have jointly announced the completion...

Company Medical Device

Jenscare Scientific’s LuX-Valve Plus Shows Positive One-Year Results in TRAVEL II Study

Fineline Cube Nov 1, 2024

Ningbo-based structural heart disease device manufacturer Jenscare Scientific Co., Ltd (HKG: 9877) has announced the...

Company

Biogen Reports Q3 2024 Sales Dip, Raises Full-Year Guidance

Fineline Cube Nov 1, 2024

US biotechnology company Biogen Inc. (NASDAQ: BIIB) reported global sales of USD 2.466 billion for...

Company Drug

Tasly Pharmaceuticals Gets FDA Approval for Acute Ischemic Stroke Cell Therapy Clinical Study

Fineline Cube Nov 1, 2024

China-based Tasly Pharmaceuticals (SHA: 600535) has announced that it has received approval from the US...

Company Deals

HutchMed to Receive $20 Million Milestone Payment from Takeda for Fruzaqla Sales

Fineline Cube Nov 1, 2024

China-based HutchMed (China) Ltd (NASDAQ: HCM; HKG: 0013) is poised to receive a USD 20...

Company Drug

Zhejiang Huahai Pharmaceutical Gets New Zealand Approval for Asthma Bispecific Antibody Trial

Fineline Cube Nov 1, 2024

Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) has announced receiving clinical trial approval in New...

Company Drug

Youcare Pharmaceutical Group Gets NMPA Approval for YKYY015 Phase I Study

Fineline Cube Nov 1, 2024

China-based Youcare Pharmaceutical Group (SHA: 688658) has announced that it has received approval from the...

Company Drug

Innovent Biologics Reports Q3 2024 Sales Exceeding RMB 2.3 Billion, Up 40% YOY

Fineline Cube Nov 1, 2024

China-based Innovent Biologics Inc., (HKG: 1801) has announced product sales exceeding RMB 2.3 billion (USD...

Company Drug

CStone Pharmaceuticals’ Sugemalimab Wins UK Approval for NSCLC Treatment

Fineline Cube Oct 31, 2024

China-based CStone Pharmaceuticals (HKG: 2616) has received marketing approval from the UK Medicines and Healthcare...

Company

Dizal Pharmaceutical’s Q3 2024 Revenues Soar 236% YOY on Strong Product Sales

Fineline Cube Oct 31, 2024

China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) has released its financial report for the third...

Company

Amgen Reports Q3 2024 Revenues of USD 8.5 Billion, Marking a 23% YOY Increase

Fineline Cube Oct 31, 2024

US biotechnology company Amgen (NASDAQ: AMGN) has announced its financial results for the third quarter...

Company Deals

HOB Biotech Group and Sino Biopharmaceutical Ltd Form Strategic Partnership in Allergy Treatments

Fineline Cube Oct 31, 2024

Jiangsu-based HOB Biotech Group Corp., Ltd (SHA: 688656) has announced a strategic cooperation agreement with...

Company

Sandoz Q3 2024 Sales Boosted by Biosimilars and Generics, Up 12% YOY

Fineline Cube Oct 31, 2024

Switzerland-based Sandoz (SWX: SDZ) has published its financial statements for the third quarter of 2024,...

Company

Junshi Biosciences Reports Q3 2024 Financials with Revenue Growth and Narrowed Losses

Fineline Cube Oct 31, 2024

Junshi Biosciences (HKG: 1877; SHA: 688180) has released its financial results for the third quarter...

Posts pagination

1 … 217 218 219 … 608

Recent updates

  • Hengrui’s HRS-7535 GLP-1R Agonist Cleared for Hypertension with Obesity Study in China
  • Merck and Abbisko’s Pimicotinib NDA Accepted by FDA for TGCT, Building on China Approval
  • Hisoar Pharma Invests RMB 150 Million in Wanbangde’s WP205 for ALS, Securing 15 % Global Revenue Share
  • FDA Approves Zycubo as First Therapy for Pediatric Menkes Disease, Targeting Ultra‑Rare Copper Deficiency Disorder
  • AbbVie Commits $100 Billion US Investment and TrumpRx Expansion for Tariff Relief
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hengrui’s HRS-7535 GLP-1R Agonist Cleared for Hypertension with Obesity Study in China

Company Drug

Merck and Abbisko’s Pimicotinib NDA Accepted by FDA for TGCT, Building on China Approval

Company Deals

Hisoar Pharma Invests RMB 150 Million in Wanbangde’s WP205 for ALS, Securing 15 % Global Revenue Share

Company Drug

FDA Approves Zycubo as First Therapy for Pediatric Menkes Disease, Targeting Ultra‑Rare Copper Deficiency Disorder

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.